Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E17.74 EPS (ttm)5.31 Insider Own9.30% Shs Outstand2.54B Perf Week4.34%
Market Cap239.81B Forward P/E16.98 EPS next Y5.55 Insider Trans-0.80% Shs Float2.50B Perf Month3.24%
Income12.45B PEG2.49 EPS next Q1.21 Inst Own12.10% Short Float0.17% Perf Quarter21.94%
Sales51.64B P/S4.64 EPS this Y66.90% Inst Trans0.02% Short Ratio1.86 Perf Half Y19.65%
Book/sh20.37 P/B4.63 EPS next Y10.16% ROA8.70% Target Price99.50 Perf Year33.72%
Cash/sh2.80 P/C33.72 EPS next 5Y7.13% ROE17.60% 52W Range71.88 - 93.65 Perf YTD22.64%
Dividend2.83 P/FCF45.86 EPS past 5Y7.70% ROI11.50% 52W High0.65% Beta0.59
Dividend %3.00% Quick Ratio0.80 Sales past 5Y0.20% Gross Margin69.00% 52W Low31.13% ATR1.45
Employees105000 Current Ratio0.90 Sales Q/Q2.10% Oper. Margin26.60% RSI (14)67.71 Volatility1.28% 1.02%
OptionableYes Debt/Eq0.65 EPS Q/Q-4.80% Profit Margin23.90% Rel Volume2.44 Prev Close90.23
ShortableYes LT Debt/Eq0.48 EarningsJul 18 BMO Payout55.20% Avg Volume2.23M Price94.26
Recom1.50 SMA203.43% SMA507.49% SMA20015.70% Volume5,449,615 Change4.47%
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Jul-18-19 04:16PM  Pharma Giant Flirts With Record High As Copycat Drugs Gain Steam Investor's Business Daily
03:09PM  Novartis AG (NVS) Q2 Earnings Call Transcript Motley Fool
11:12AM  Pharma Giant Flirts With Record High As Copycat Drugs Gain Steam Investor's Business Daily
11:11AM  Is a Beat in Store for Glaxo (GSK) This Earnings Season? Zacks
11:06AM  [video]Novartis Up on Financial Results and Potential Resolution of Kickback Case TheStreet.com
09:58AM  Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance Zacks
09:52AM  Stocks Stumble As Netflix Dives; Dow Jones Stock IBM Breaks Out, Apple Upgraded Investor's Business Daily
05:59AM  Novartis raises full-year targets, aims to settle U.S. lawsuit Reuters
04:58AM  Novartiss Brightened Outlook Pushes Shares to All-Time High Bloomberg
02:29AM  StockBeat: A Sea of Red as Earnings Live Down to Expectations Investing.com
01:22AM  Novartis raises 2019 guidance, helped by Sandoz generics unit Reuters
Jul-17-19 03:22PM  The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On Motley Fool
10:48AM  Why Earnings Season Could Be Great for Novartis (NVS) Zacks
10:24AM  Merck's Antibiotic Recarbrio Gets FDA Nod for Infections Zacks
10:19AM  Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel Zacks
09:15AM  Trade Talk Cools Off Record-Setting Market Zacks
Jul-16-19 06:05PM  Should You Pick Up Novartis (NVS) Before Q2 Earnings? Zacks
04:19PM  Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings? Zacks
02:14PM  Eisai boosts focus on Alzheimer's with new research facility, funding American City Business Journals
10:07AM  Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA Zacks
08:17AM  Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall Zacks
Jul-15-19 09:05AM  J&J Falls Amid Reports of Criminal Probe Into Talcum Powder Zacks
Jul-14-19 12:35AM  GSK to appoint Jonathan Symonds as chairman Financial Times
Jul-12-19 05:05PM  What Happened in the Stock Market Today Motley Fool
10:24AM  Amgen & Novartis' Alzheimer Studies End in Another Failure Zacks
10:19AM  Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug Benzinga
09:47AM  Aimmune Down on Negative ICER Review on Allergy Candidate Zacks
07:58AM  Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails Investor's Business Daily
07:24AM  The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study Benzinga
Jul-11-19 04:51PM  Amgen and Novartis drop Alzheimer's-prevention study after patients worsened MarketWatch
04:42PM  Signature Select Canadian Fund's Top 6 Buys GuruFocus.com
04:21PM  Amneal (AMRX) Down on Guidance Update & Restructuring Plan Zacks
05:14AM  Amgen, Novartis abandon two Alzheimers drug studies Financial Times
Jul-10-19 05:40PM  Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill Zacks
04:41PM  How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug Investor's Business Daily
01:16PM  The 10 Biggest Healthcare Stocks Motley Fool
12:43PM  EpiPen Shortage: Mylan (MYL) Stock Falls on Continued Scarce Supply InvestorPlace
10:22AM  Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset Zacks
09:22AM  Mylan Falls on Report That EpiPen Shortage Is Hurting Patients and Pharmacists TheStreet.com
07:17AM  The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV Benzinga
Jul-09-19 06:01PM  Novo Nordisk Reports Encouraging Data From Hemophilia Studies Zacks
05:55PM  Bayer-J&J Announce Positive Xarelto Data in Children with VTE Zacks
05:52PM  Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline Zacks
05:48PM  Aerie Completes Enrollment Under Rhopressa Study in Japan Zacks
12:38PM  The Fundamental Problems of Tilray Stock Are Just Getting Worse InvestorPlace
11:54AM  UPDATE 3-Novartis to sell epinephrine shot in U.S. pharmacies amid EpiPen shortage Reuters
07:45AM  Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage Reuters
Jul-08-19 03:36PM  Novartis' Struggle With Payers Over Zolgensma Is Overblown GuruFocus.com
Jul-05-19 08:09PM  The Top 10 Biotechnology Companies (JNJ, ROG.VX) Investopedia
08:55AM  The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight Benzinga
Jul-03-19 10:23AM  Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab Zacks
Jul-02-19 05:09PM  Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx Zacks
02:57PM  Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran Zacks
09:13AM  Market Morning: Swiss Bans Stocks from EU, Bitcoin Breaks Below $10K, USTR Wants More Tariffs Market Exclusive
09:01AM  AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label Zacks
Jul-01-19 06:12PM  Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer Zacks
09:25AM  Atara Reports Initial Data for Multiple Sclerosis Candidate Zacks
08:19AM  3 Small-Cap Biotech Stocks That Soared Last Week Motley Fool
07:10AM  Miraca and Seventh Sense Biosystems, Inc. Announce Strategic Investment and Distribution Agreement PR Newswire
Jun-28-19 09:56AM  Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View Zacks
Jun-27-19 04:38PM  Biogen Drug Gets a Thumbs Down From Neurologist Barrons.com
10:30AM  FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review Zacks
09:50AM  Dova Receives Approval for Doptelet in Europe, Stock Up Zacks
09:37AM  Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits Zacks
Jun-26-19 05:51PM  Is Allergan a Good Deal for AbbVie? Zacks
06:07AM  Conatus' Emricasan Lags Primary Goal in Liver Function Study Zacks
Jun-25-19 07:51AM  Novartis wins Gilenya reprieve as judge blocks generics, for now Reuters
Jun-24-19 05:00PM  UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial Reuters
Jun-23-19 04:56PM  The 5 Most Expensive Drugs In US: What You Should Know Benzinga
Jun-22-19 09:33AM  This would be the worst-case scenario for health stocks, according to UBS MarketWatch
Jun-21-19 05:36PM  Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval Zacks
11:50AM  UPDATE 1-U.S. group says Novartis MS drug price out of line with benefit Reuters
01:40AM  U.S. group says Novartis MS drug price out of line with benefit Reuters
Jun-20-19 04:23PM  From generic drugs to gummies: Boulder CBD company buys Novartis pharmaceutical plant in Broomfield for $18.8M American City Business Journals
Jun-19-19 09:30AM  NVS or NVO: Which Is the Better Value Stock Right Now? Zacks
Jun-18-19 05:11PM  Online pharmacy flags possible new impurity in blood pressure drug Reuters
09:45AM  Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status Zacks
09:41AM  Alcon Inc. -- Moody's assigns Baa2 ratings to Alcon Inc.'s unsecured debt facilities Moody's
08:03AM  Roche's Rozlytrek Gets Approval in Japan for Solid Tumors Zacks
Jun-17-19 05:26PM  J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study Zacks
03:41PM  Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz Zacks
Jun-13-19 10:35PM  Bluebird Bio prices gene therapy at nearly $1.8m Financial Times
05:40PM  Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris Zacks
02:34PM  Top Analyst Reports for Visa, Netflix & Accenture Zacks
09:36AM  Ligand Inks Oncology Drug Discovery Deal With PhoreMost Zacks
07:30AM  A Stock Fund Challenges the Definition of Growth. Its Paying Off. Barrons.com
Jun-12-19 06:33PM  Roche's Rituxan Gets Priority Review for Blood Disorder Zacks
06:21PM  Novartis Reports Data on Cosentyx for Psoriatic Arthritis Zacks
Jun-11-19 02:50PM  Stoke Therapeutics boosts IPO goal by 40 percent American City Business Journals
Jun-10-19 05:30PM  Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug Zacks
11:48AM  Curium Bidco S.a.r.l -- Moody's assigns B2 CFR to Curium Bidco S.a.r.l.; outlook stable Moody's
09:39AM  Roche Receives FTC Request for Further Data on Spark Buyout Zacks
Jun-07-19 05:00PM  Celgene's Filing for Ozanimod Accepted for Review in US/EU Zacks
12:25PM  Sanofi's Leadership Transition: What You Need To Know Benzinga
11:53AM  New Sanofi CEO 2019: 8 Things to Know About Paul Hudson InvestorPlace
11:28AM  Heres What Hedge Funds Think About Novartis AG (NVS) Insider Monkey
10:59AM  Sanofi Taps Novartis Executive as CEO in Race for New Drugs Bloomberg
09:09AM  Novartis Appoints New Pharma Unit Head, Gives Other Updates Zacks
07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
03:51AM  Sanofi appoints top Novartis executive as new chief Financial Times
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; TRIO; and Verily. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerMay 28Buy14.00168,6302,360,8201,769,641May 30 09:27 PM
Novartis Bioventures Ltd10% OwnerApr 26Sale1.03138,704142,8654,049,804Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 25Sale1.03563,096579,9894,188,508Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 24Sale1.0316,40316,8954,751,604Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 23Sale1.0327,55428,3814,768,007Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 22Sale0.977,1006,8874,795,561Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 15Sale0.9928,79428,5064,802,661Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 12Sale1.0430,90832,1444,831,455Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 11Sale1.0857,43862,0334,862,363Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 10Sale1.09140,230152,8514,919,801Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 09Sale1.0132,99133,3215,060,031Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 08Sale1.0227,52528,0765,093,022Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 05Sale1.0224,66125,1545,120,547Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 04Sale1.0147,90048,3795,145,208Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 03Sale0.9658,03355,7125,193,108Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 02Sale0.9751,75450,2015,251,141Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale0.95116,909111,0645,302,895Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale1.9020,61039,1592,079,394Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale1.85106,540197,0992,100,004Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale0.9163,10057,4215,419,804Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 28Sale0.9488,83583,5055,482,904Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 27Sale0.9950,74950,2425,571,739Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 26Sale1.01177,762179,5405,622,488Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 15Sale1.9243,80084,0962,206,544Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 14Sale1.8813,80025,9442,250,344Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 13Sale2.12132,738281,4052,264,144Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerAug 20Sale2.3020,38846,8922,396,882Aug 22 04:34 PM
Novartis Bioventures Ltd10% OwnerAug 20Sale3.905,30020,6705,800,250Aug 22 04:07 PM
Novartis Bioventures Ltd10% OwnerAug 17Sale2.108,70018,2702,417,270Aug 20 05:12 PM
Novartis Bioventures Ltd10% OwnerAug 16Sale2.108,80818,4972,425,970Aug 20 05:12 PM
Novartis Bioventures Ltd10% OwnerAug 15Sale2.152,6355,6652,434,778Aug 16 04:18 PM
Novartis Bioventures Ltd10% OwnerAug 14Sale2.263,3007,4582,437,413Aug 16 04:18 PM
Novartis Bioventures Ltd10% OwnerAug 13Sale2.361,6003,7762,440,713Aug 14 05:05 PM
Novartis Bioventures Ltd10% OwnerAug 10Sale2.445,61513,7012,442,313Aug 14 05:05 PM
Novartis Bioventures Ltd10% OwnerAug 09Sale2.482355832,447,928Aug 10 04:29 PM
Novartis Bioventures Ltd10% OwnerAug 08Sale2.781,0002,7802,448,163Aug 10 04:29 PM
Novartis Bioventures Ltd10% OwnerAug 07Sale2.971,7395,1652,449,163Aug 08 04:21 PM
Novartis Bioventures Ltd10% OwnerAug 06Sale3.022,9428,8852,450,902Aug 08 04:21 PM
Novartis Bioventures Ltd10% OwnerAug 02Sale3.334,70215,6582,453,844Aug 06 04:22 PM
Novartis Bioventures Ltd10% OwnerAug 01Sale3.228,18126,3432,458,546Aug 02 04:33 PM
Novartis Bioventures Ltd10% OwnerJul 31Sale3.074,50013,8152,466,727Aug 02 04:33 PM
Novartis Bioventures Ltd10% OwnerJul 30Sale3.272,0006,5402,471,227Jul 31 04:16 PM
Novartis Bioventures Ltd10% OwnerJul 27Sale3.386,45821,8282,473,227Jul 31 04:16 PM
Novartis Bioventures Ltd10% OwnerJul 26Sale3.637,93728,8112,479,685Jul 27 04:21 PM
Novartis Bioventures Ltd10% OwnerJul 25Sale3.8412,46047,8462,487,622Jul 27 04:21 PM
Novartis Bioventures Ltd10% OwnerJul 24Sale4.117002,8772,500,082Jul 25 04:35 PM
Novartis Bioventures Ltd10% OwnerJul 23Sale4.2530,600130,0502,500,782Jul 25 04:35 PM